Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of ACT-128800 (Ponesimod) in Healthy Males
NCT02126956Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2009
- Primary completion
- Apr 2009
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ponesimod in multiple sclerosis (MS), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Cumulative recovery of total radioactivity in urine at 240 hours and Cumulative recovery of total radioactivity in faeces at 240 hours. Started Mar 2009; status: completed.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02126956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126956.